Skip to main content
Log in

A pharmacological imaging challenge based on 11C-buprenorphine PET-MRI to explore the response to opioids in humans

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Auvity S, Goutal S, Caillé F, Vodovar D, Pruvost A, Wimberley C, et al. Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. Neuropsychopharmacology. 2021;46:1220–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Upadhyay J, Anderson J, Schwarz AJ, Coimbra A, Baumgartner R, Pendse G, et al. Imaging drugs with and without clinical analgesic efficacy. Neuropsychopharmacology. 2011;36:2659–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tournier N, Comtat C, Lebon V, Gennisson J-L. Challenges and perspectives of the hybridization of PET with functional MRI or ultrasound for neuroimaging. Neuroscience. 2021;474:80–93.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We gratefully thank Vincent Brulon and Maud Goislard for technical assistance.

Funding

This work was performed on a platform member of France Life Imaging network (grant ANR-11-INBS-0006) and was funded by the “Lidex-PIM” project funded by the IDEX Paris-Saclay, ANR-11-IDEX-0003–02.

Author information

Authors and Affiliations

Authors

Contributions

Claire Leroy, Michel Bottlaender, and Nicolas Tournier contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Claire Leroy, Sébastien Goutal, Louise Breuil, Philippe Gervais, Hamza Cherkaoui, Philippe Ciuciu, Sylvain Auvity, Dominique Vodovar, Claude Comtat, Vincent Lebon, and Michel Bottlaender. The first draft of the manuscript was written by Claire Leroy and Nicolas Tournier and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nicolas Tournier.

Ethics declarations

Ethics approval/clinical trial registration

This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the French Ethics Committee for Biomedical Research (Study CEA 100–040; EudraCT 2017–001897-41). Registered 02 December 2017.

Consent to participate

Signed informed consent was obtained from all individual participants included in the study.

Consent for publication

The authors affirm that human research participants provided informed consent for publication of the images.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leroy, C., Goutal, S., Breuil, L. et al. A pharmacological imaging challenge based on 11C-buprenorphine PET-MRI to explore the response to opioids in humans. Eur J Nucl Med Mol Imaging 50, 3153–3154 (2023). https://doi.org/10.1007/s00259-023-06253-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-023-06253-w

Navigation